Abnormal Restriction Pattern of PIP Gene Associated with Human Primary Prostate Cancers

Autiero, Monica; Culerrier, Raphael; Bouchier, Christiane; Basmaciogullari, Stephane; Gaubin, Muriel; Marhomy, Sandrine El; Blanchet, Pascal; Paradis, Valerie; Jardin, Alain; Guardiola, John; Piatier-Tonneau, Dominique
June 1999
DNA & Cell Biology;Jun99, Vol. 18 Issue 6, p481
Academic Journal
The PIP gene, localized in the 7q34 region that contains a number of fragile sites such as FRA 7H and FRA TI, codes for gp17/PIP, a protein secreted by breast apocrine tumors. We analyzed the integrity of this gene in 20 tumors of the urogenital tract. We found rearranged Eco RI fragments in 5 of 15 primary prostate carcinomas. No rearrangement was found in normal prostates derived from five patients undergoing prostatocystectomy during treatment of bladder cancers. By Southern blot hybridization with PIP gene exon-specific probes, the rearrangements were mapped at or near the 3' end of the gene. These abnormalities were found, not only in the neoplastic cells invading the prostatic tissues, but also in seminal vesicles without histologic tumoral features. These data suggest a critical role of the PIP gene or neighboring genes in prostate cancer.


Related Articles

  • Is TIG1 a New Tumor Suppressor in Prostate Cancer? Lotan, Reuben // JNCI: Journal of the National Cancer Institute;4/3/2002, Vol. 94 Issue 7, p469 

    Reports the identification of a gene whose decreased expression may contribute to the development and progression of prostate cancer. Use of a selective subtractive differential gene display; Induction of the gene by the synthetic retinoid tazarotene in human skin raft cultures; Indication made...

  • Viral Based Gene Therapy for Prostate Cancer. Yi Lu // Current Gene Therapy;Jul2001, Vol. 1 Issue 2, p183 

    In the last few years, significant advances in gene therapy have been made as a result of advances in many areas of molecular and cell biology, including the improvement of both viral and nonviral gene delivery systems, discovery of new therapeutic genes, better understanding of mechanism of...

  • New gene expression-based model predicts clinical PCa. Newman, Laura // Urology Times;May2002, Vol. 30 Issue 5, p11 

    Reports on a gene expression-based model predicting the behavior of prostate cancer in men in Bethesda, Maryland. Prediction of the recurrence of the tumor following prostatectomy; Percentage of the accuracy rate of the method; Gene expressions of the model.

  • Targeting of adenoviral vectors for gene therapy of prostate cancer. Bangma, C H // Prostate Cancer & Prostatic Diseases;2000, Vol. 3 Issue 4, p308 

    The transduction of cytotoxic genes by adenoviral vectors into prostatic cells offers a new entity for the treatment of prostate cancer. Current adenoviral vectors cannot infect prostatic cells selectively, and expression of therapeutic genes is often too low to be efficient. Bispecific...

  • Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Goessl, C; Müller, M; Miller, K // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS17 

    Although prostate specific antigen (PSA) represents a sensitive serum tumour marker for prostate cancer, its use is limited by an insufficient specificity. Therefore, DNA-based molecular tumour markers might increase specificity in the detection of primary and recurrent prostate cancer. The...

  • Adenoviral mediated gene therapy for prostate cancer: studies on vector tropism and payload. Bangma, C H; Kraaij, R; Oomen, M H A; Th Van Rijswijk, A L C; de Ridder, C M A // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS5 

    Adenovirus (Ad5) mediated gene therapy for prostate cancer offers a new therapeutic modality. Payloads of various origins (cytotoxic, immunomodulatory, repair genes) have been applied in experimental settings and even in clinical phase I trials to alter tumour growth. We report here on in vitro...

  • Evidence for an association between the SRD5A2 (type II steroid 5. Margiotti, K.; Sangiuolo, F.; De Luca, A.; Froio, F.; Pearce, C.L.; Ricci-Barbini, V.; Micali, F.; Bonaf\`e, M.; Franceschi, C.; Dallapiccola, B.; Novelli, G.; Reichardt, J.K.V. // Disease Markers;2000, Vol. 16 Issue 3/4, p147 

    We have investigated the contributions of three polymorphic markers in the SRD5A2 gene to prostate cancer in a group of Italian patients. We have genotyped cases and controls for a polymorphic (TA)

  • CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. Cheng, Liang; Sun, Jian // JNCI: Journal of the National Cancer Institute;05/01/96, Vol. 88 Issue 9, p607 

    Seeks to establish a relevant ex vivo tumor model for gene therapy studies of human prostate cancer. Morphological characteristics and culture behavior of human primary prostate cancer CWR22 cells in the collagen gel culture system; Expression of transgenic cytokines in transfected CWR22 cells;...

  • Gene therapy finds cracks in prostate cancer's defenses. Overmyer, Mac // Urology Times;Sep96, Vol. 24 Issue 9, p22 

    Discusses the use of gene therapy on prostate cancer. Comparison with battlefield tactics; Thymidine kinase and adenoviruses; Cell-specific therapy; Subverting cellular machinery.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics